Abstract Library

#4501 Efficacy and safety of surufatinib in unresectable or metastatic grade 3 neuroendocrine tumours (NET G3): A national multi-centre, retrospective study

Introduction: Currently, there are limited treatment options for NET G3 and therapeutics for NET G1/2 may be considered as alternatives.

Conference:

Presenting Author: Hao J

Authors: Wang J, Zhang N, Liang Y, Long J, Chi Y,

Keywords: surufatinib, NET G3,

#4455 Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC

Introduction: HG-GEP-NEN are classified into neuroendocrine tumours grade 3 (NET G3) and neuroendocrine carcinomas (NEC). This distinction is crucial as it affects patient prognosis and treatments but can be challenging.

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Solstad O, Oudijk L, Bräutigam K, Bani M,

Keywords: HG-GEP-NEN, neuroendocrine neoplasm, NEC, NET G3, Classification, Review, criteria, diagnosis, pathology,

#4403 Ki-67 index cut-off values and survival prognostication in neuroendocrine neoplasms: Machine learning-based insights

Introduction: The current grading system for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is based on Ki-67 index and/or mitotic rate. By definition, high-grade NEN (neuroendocrine tumour grade 3 [NET G3] and neuroendocrine carcinoma [NEC]) have a Ki-67 >20%, while NET G1 have a Ki-67

Conference:

Presenting Author:

Authors: Melhorn P, Berchtold L, Mazal P, Raderer M, Kiesewetter B,

Keywords: neuroendocrine neoplasm, prognosis, ki-67 index,

#4376 Analysis of clinical features and prognosis of 195 cases of gastrointestinal and pancreatic neuroendocrine tumours

Introduction: Neuroendocrine tumours are most common in the stomach and pancreas. With the Ki-67 positive index of NET G3 and NEC both above 20%, there is a view that NET G3 will not evolve into NEC.

Conference:

Presenting Author:

Authors: Dai C, Tang Y, Zhu Y, Tu R, Wang Y,

Keywords: gastroenteropancreatic neuroendocrine tumour, Clinical characteristics, prognosis,

#4354 Analysis of gastric NENS in the Czech neuroendocrine tumour registry (2009-2024)

Introduction: Czech Neuroendocrine Tumour Registry is collecting data of NEN patients and their treatment since 2009. We have already analysed SI NENs, pancreatic and thymic NENs. Now we focused on analysis of gastric NENs.

Conference:

Presenting Author:

Authors: Barkmanova J, Sedlackova E,

Keywords: registry, gastric neuroendocrine neoplasia,